rs35365413

Variant summary

Our verdict is Benign. The variant received -13 ACMG points: 3P and 16B. PM1PP3BP4_StrongBP6_Very_StrongBS1

The NM_019098.5(CNGB3):​c.1405T>G​(p.Tyr469Asp) variant causes a missense change. The variant allele was found at a frequency of 0.000431 in 1,614,036 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. Y469N) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.0024 ( 1 hom., cov: 32)
Exomes 𝑓: 0.00022 ( 0 hom. )

Consequence

CNGB3
NM_019098.5 missense

Scores

6
10
3

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts P:1U:2B:6

Conservation

PhyloP100: 4.11

Publications

7 publications found
Variant links:
Genes affected
CNGB3 (HGNC:2153): (cyclic nucleotide gated channel subunit beta 3) This gene encodes the beta subunit of a cyclic nucleotide-gated ion channel. The encoded beta subunit appears to play a role in modulation of channel function in cone photoreceptors. This heterotetrameric channel is necessary for sensory transduction, and mutations in this gene have been associated with achromatopsia 3, progressive cone dystrophy, and juvenile macular degeneration, also known as Stargardt Disease. [provided by RefSeq, Feb 2010]
CNGB3 Gene-Disease associations (from GenCC):
  • achromatopsia 3
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), G2P, PanelApp Australia
  • CNGB3-related retinopathy
    Inheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
  • cone dystrophy
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • achromatopsia
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
  • severe early-childhood-onset retinal dystrophy
    Inheritance: Unknown Classification: LIMITED Submitted by: Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -13 ACMG points.

PM1
In a hotspot region, there are 2 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 1 benign, 4 uncertain in NM_019098.5
PP3
Multiple lines of computational evidence support a deleterious effect 6: AlphaMissense, BayesDel_noAF, MutationAssessor, PROVEAN, REVEL, REVEL [when max_spliceai, FATHMM_MKL, MetaRNN, MutationTaster was below the threshold]
BP4
Computational evidence support a benign effect (MetaRNN=0.041806072).
BP6
Variant 8-86628994-A-C is Benign according to our data. Variant chr8-86628994-A-C is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 5227.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS1
Variant frequency is greater than expected in population afr. GnomAd4 allele frequency = 0.00244 (371/152284) while in subpopulation AFR AF = 0.00835 (347/41570). AF 95% confidence interval is 0.00762. There are 1 homozygotes in GnomAd4. There are 175 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CNGB3NM_019098.5 linkc.1405T>G p.Tyr469Asp missense_variant Exon 12 of 18 ENST00000320005.6 NP_061971.3 Q9NQW8-1
CNGB3XM_011517138.3 linkc.991T>G p.Tyr331Asp missense_variant Exon 10 of 16 XP_011515440.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CNGB3ENST00000320005.6 linkc.1405T>G p.Tyr469Asp missense_variant Exon 12 of 18 1 NM_019098.5 ENSP00000316605.5 Q9NQW8-1
CNGB3ENST00000681546.1 linkn.1225T>G non_coding_transcript_exon_variant Exon 7 of 13
CNGB3ENST00000681746.1 linkn.1405T>G non_coding_transcript_exon_variant Exon 12 of 19 ENSP00000505959.1 A0A5J6DSN8

Frequencies

GnomAD3 genomes
AF:
0.00244
AC:
371
AN:
152166
Hom.:
1
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00837
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00144
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.000959
GnomAD2 exomes
AF:
0.000589
AC:
148
AN:
251070
AF XY:
0.000487
show subpopulations
Gnomad AFR exome
AF:
0.00824
Gnomad AMR exome
AF:
0.000318
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.000489
GnomAD4 exome
AF:
0.000222
AC:
324
AN:
1461752
Hom.:
0
Cov.:
32
AF XY:
0.000190
AC XY:
138
AN XY:
727180
show subpopulations
African (AFR)
AF:
0.00810
AC:
271
AN:
33470
American (AMR)
AF:
0.000447
AC:
20
AN:
44710
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26126
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39688
South Asian (SAS)
AF:
0.0000232
AC:
2
AN:
86256
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
53420
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5766
European-Non Finnish (NFE)
AF:
8.99e-7
AC:
1
AN:
1111928
Other (OTH)
AF:
0.000497
AC:
30
AN:
60388
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.481
Heterozygous variant carriers
0
26
53
79
106
132
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00244
AC:
371
AN:
152284
Hom.:
1
Cov.:
32
AF XY:
0.00235
AC XY:
175
AN XY:
74470
show subpopulations
African (AFR)
AF:
0.00835
AC:
347
AN:
41570
American (AMR)
AF:
0.00144
AC:
22
AN:
15278
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3472
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5178
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4822
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10626
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
68024
Other (OTH)
AF:
0.000949
AC:
2
AN:
2108
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.508
Heterozygous variant carriers
0
20
40
60
80
100
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000813
Hom.:
3
Bravo
AF:
0.00279
ESP6500AA
AF:
0.00794
AC:
35
ESP6500EA
AF:
0.00
AC:
0
ExAC
AF:
0.000782
AC:
95

ClinVar

Significance: Benign/Likely benign
Submissions summary: Pathogenic:1Uncertain:2Benign:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:3
Feb 22, 2016
Eurofins Ntd Llc (ga)
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Dec 11, 2023
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: CNGB3 c.1405T>G (p.Tyr469Asp) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00059 in 251070 control chromosomes, predominantly at a frequency of 0.0082 within the African or African-American subpopulation in the gnomAD database, including 1 homozygote. The observed variant frequency within African or African-American control individuals in the gnomAD database is approximately 1.64 fold of the estimated maximal expected allele frequency for a pathogenic variant in CNGB3 causing Achromatopsia phenotype (0.005), suggesting that the variant is a benign polymorphism found primarily in populations of African or African-American origin. c.1405T>G has been reported in the literature in settings of limited gene panel testing in heterozygous individuals with no reported second variant affected with achromatopsia (e.g. Mayer_2017, Weisschuh_2020), in at least one compound heterozygous individual affected with macular degeneration (e.g. Sun_2020, Nishiguchi_2005), or by WES in a heterozygous individual affected with severe Retinitis Pigmentosa (e.g. Ganapathi_2022). These report(s) do not provide unequivocal conclusions about association of the variant with Achromatopsia. One publication reports experimental evidence evaluating an impact on protein function, suggesting the variant may enhance the intrinsic (ligand independent) gating properties of CNG channels in vitro, however, additional evidence is necessary to allow convincing conclusions about the variant effect in disease (e.g. Meighan_2015). The following publications have been ascertained in the context of this evaluation (PMID: 35672425, 28795510, 26106334, 15712225, 32913385, 31544997). Five submitters have cited clinical-significance assessments for this variant to ClinVar after 2014, classifying the variant as benign (n=2), likely benign (n=1), uncertain significance (n=1), or likely pathogenic (n=1). Based on the conflicting evidence outlined above, the variant was classified as likely benign. -

Feb 05, 2024
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The p.Tyr469Asp variant in CNGB3 is classified as likely benign because it has been identified in 0.8% (347/41448) of African chromosomes, including 1 homozygote by gnomAD (http://gnomad.broadinstitute.org). ACMG/AMP Criteria applied: BS1. -

Achromatopsia 3 Pathogenic:1Uncertain:1
Mar 27, 2017
Molecular Genetics Laboratory, Institute for Ophthalmic Research
Significance:Likely pathogenic
Review Status:no assertion criteria provided
Collection Method:research

- -

Sep 19, 2017
Counsyl
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:clinical testing

This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com. -

not provided Benign:2
Feb 01, 2024
CeGaT Center for Human Genetics Tuebingen
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

CNGB3: BS2 -

Jan 23, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Severe early-childhood-onset retinal dystrophy Uncertain:1
Mar 01, 2005
OMIM
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:literature only

- -

Achromatopsia Benign:1
Jan 08, 2020
Natera, Inc.
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.80
BayesDel_addAF
Uncertain
0.038
T
BayesDel_noAF
Pathogenic
0.29
CADD
Uncertain
24
DANN
Uncertain
0.99
DEOGEN2
Uncertain
0.48
T
Eigen
Uncertain
0.36
Eigen_PC
Uncertain
0.29
FATHMM_MKL
Uncertain
0.94
D
LIST_S2
Uncertain
0.91
D
M_CAP
Uncertain
0.27
D
MetaRNN
Benign
0.042
T
MetaSVM
Pathogenic
0.85
D
MutationAssessor
Pathogenic
2.9
M
PhyloP100
4.1
PrimateAI
Uncertain
0.61
T
PROVEAN
Pathogenic
-8.7
D
REVEL
Pathogenic
0.74
Sift
Benign
0.055
T
Sift4G
Uncertain
0.060
T
Polyphen
0.97
D
Vest4
0.92
MVP
0.98
MPC
0.17
ClinPred
0.12
T
GERP RS
4.8
Varity_R
0.41
gMVP
0.79
Mutation Taster
=91/9
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs35365413; hg19: chr8-87641222; API